

COLO699 ADC RLU's (n=1)
90000
85000
80000
75000
70000
65000
60000
55000
50000
45000
40000
35000
30000
25000
20000
COLO699 ADC RLU's (n=2)
30000
40000
50000
60000
70000
80000

Figure 1




COLO-699 ADC Avg. RLU's
54000
52000
50000
48000
46000
44000
42000
40000
38000
36000
34000
32000
30000
CHL-1 ADC Avg. RLU's
10000
20000
30000
40000
50000
60000

Figure 2

Figure 3


2e^(-dCt)
3.00E-001
2.80E-001
2.60E-001
2.40E-001
2.20E-001
2.00E-001
1.80E-001
1.60E-001
1.40E-001
1.20E-001
1.00E-001
8.00E-002
6.00E-002
4.00E-002
2.00E-002
Adipose Normal
Bladder Normal
Brain Normal
Breast Normal
Cervix Tumor
Esophagus Normal
Eye Normal
Haematop... Normal
Head & Neck Tumor
Heart Normal
Large Intes... Normal
Liver Normal
Lung Tumor
Ovary Normal
Pancreas Tumor
Pituitary Gl... Normal
Prostate Normal
Skeletal M ... Normal
Skin Tumor
Stomach Normal
Testis Normal
Thyroid Tumor
Ureter Normal
Uterus Tumor
Tissue of Origin, Normal, tumor, metastasis




Figure 4



CHL-1
Colo-699
A2058
LOX-IMVI
2-3+
2+
1+
Negative
~10000 receptors*
~5000 receptors*
~1000
< 50 receptors*

Figure 5



CDH19 2G6 x I2C
L1.2
L1.2 – CDH19
CHL-1 Strong expr.
A2058 Weak expr.
HPB-ALL Hum CD3
4119 LnPx Macaque CD3

Figure 6




Figure 6 (continued)




Figure 6 (continued)




Figure 6 (continued)




Figure 6 (continued)




Figure 6 (continued)




Figure 6 (continued)




Figure 6 (continued)




Figure 6 (continued)







Figure 6 (continued)






EC_{50}	2G6 x I2C	25F8.1 x I2C	26D1.1 x I2C	19B5.1 x I2C	26F12.1 x I2C	20D3.1 x I2C	4F7 x I2C	22D1.1 x I2C	23A10.3 x I2C
[pg/ml]	261	6973	3487	14236	6748	23796	16168	14379	346
pMolar	4.9	131	65.6	268	127	447	304	270	6.5

Figure 7



EC_{50}	2G6 x I2C	25F8.1 x I2C	26D1.1 x I2C	19B5.1 x I2C	26F12.1 x I2C	20D3.1 x I2C	4F7 x I2C	22D1.1 x I2C	23A10.3 x I2C
[pg/ml]	0.4	28	27	6.9	21	20	1842	28	3.6
fMolar	7.5	526	508	130	395	376	34630	526	67.7

Figure 7 (continued)



@ Tumors and human PBMC inoculated at a 2:1 ratio on Day 0.

Figure 8





Figure 8 (continued)



@ Tumor cells and human PBMC inoculated at a 2:1 ratio on Day

Figure 9




Figure 9 (continued)

CDH19 BiTE	EC50(pM)
2G6 x I2C	1.729
2G6.001	1.576
2G6.003	1.721
2G6.007	1.783
26F12.1 x I2C	18.48
26F12.002	19.4
26F12.004	20.74
26F12.006	72.22
26F12.008	83.43
19B5.1 x I2C	33.59
19B5.1.002	22.37
19B5.1.003	34.62
4B10.002	4.83
4B10.003	4.088
4B10.005	5.583
26D1.1 x I2C	19.19
26D1.1.003	15.53
26D1.1.004	19.77
26D1.1.005	36.42
23A10.3 x I2C	2.086
23A10.001 (B1)	1.078
23A10.001 (B2)	1.623
23A10.002	1.351
4A2.002	0.7547




Figure 10A

CDH19 BiTE	EC50[pM]
2G6 x I2C	no specific activity
2G6.001	no specific activity
2G6.003	no specific activity
2G6.007	no specific activity
26F12.1 x I2C	no specific activity
26F12.002	no specific activity
26F12.004	no specific activity
26F12.006	no specific activity
26F12.008	no specific activity
19B5.1 x I2C	no specific activity
19B5.1.002	no specific activity
19B5.1.003	no specific activity
4B10.002	no specific activity
4B10.003	no specific activity
4B10.005	no specific activity
26D1.1 x I2C	no specific activity
26D1.1.003	no specific activity
26D1.1.004	no specific activity
26D1.1.005	no specific activity
23A10.3 x I2C	no specific activity
23A10.001 (B1)	no specific activity
23A10.001 (B2)	no specific activity
23A10.002	no specific activity
4A2.002	no specific activity




Figure 10B




Figure 11





Figure 12

Figure 14






Figure 13




Figure 15




Figure 16




Figure 17



HIC Octyl 1ml SSt004:10 UV2 254nm
HIC Octyl 1ml SSt004:10 Inject
HIC Octyl 1ml SSt004:10 UV1 280nm
HIC Octyl 1ml SSt004:10 Cond
HIC Octyl 1ml SSt004:10_Edited Baseline
mAU
25.0
20.0
15.0
10.0
5.0
0.0
-5.0
-10.0
0.0
2.0
4.0
6.0
8.0
10.0
ml

Figure 18



HPB-ALL
HEK hu CDH19
CH19 2G6 302 x I2C
CH19 2G6 302 CC x I2C
Normalized To Mode
FL2-H

Figure 19




Figure 19 (continued)




Figure 19 (continued)




Figure 19 (continued)




Figure 19 (continued)




Figure 19 (continued)




Figure 19 (continued)




Figure 19 (continued)




Figure 19 (continued)




Figure 19 (continued)




Figure 19 (continued)




Figure 19 (continued)




Figure 19 (continued)




Figure 19 (continued)



HEK hu CDH19
2G6 302 x I2C
2G6 302 CC x I2C
2G6 303 x I2C
2G6 303 CC x I2C
2G6 039 x I2C
2G6 039 CC x I2C
Lysis [%]
0
20
40
60
80
BiTE Conc. [pg/ml]
10-4
10-2
100
102
104
2G6 302 x F12q0
2G6 302 CC x F12q0
2G6 303 x F12q0
2G6 303 CC x F12q0
2G6 039 x F12q0
2G6 039 CC x F12q0
Lysis [%]
0
20
40
60
80
BiTE Conc. [pg/ml]
10-2
100
102
104

Figure 20




Figure 20 (continued)